Remtolumab, CAS 1791410-27-9

Product Description: Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Khatri A, et al. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. Clin Pharmacokinet. 2018 May;57(5):613-623./[2]Havnaer A, et al. Systemic therapies in psoriasis: an update on newly approved and pipeline biologics and oral treatments. Cutis. 2019 Aug;104(2S):17-20.

CAS Number: 1791410-27-9

Molecular Weight: N/A

Compound Purity: 99.24

Research Area: Inflammation/Immunology

Solubility: H2O

Target: Interleukin Related;TNF Receptor

• Artikelnummer: MEXHY-P99940-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99940-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated